Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()

INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a treatment option in the second- or third-line palliative setting in EGFR wild-type (wt) non–small cell lung cancer (NSCLC) patients. However, response rates are low, and only approximately 25% will achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Winther-Larsen, Anne, Fledelius, Joan, Demuth, Christina, Bylov, Catharina M, Meldgaard, Peter, Sorensen, Boe S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094375/
https://www.ncbi.nlm.nih.gov/pubmed/27816687
http://dx.doi.org/10.1016/j.tranon.2016.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094375/
https://www.ncbi.nlm.nih.gov/pubmed/27816687
http://dx.doi.org/10.1016/j.tranon.2016.09.003

Ejemplares similares